Skip to main content

Day: July 15, 2020

Seanergy Maritime Holdings Corp. Regains Compliance with Nasdaq Minimum Bid Price Requirement

ATHENS, Greece, July 15, 2020 (GLOBE NEWSWIRE) — Seanergy Maritime Holdings Corp. (the “Company”) (NASDAQ: SHIP) announced today that The Nasdaq Stock Market has confirmed that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) concerning the minimum bid price of the Company’s common stock. The matter is now considered closed.About Seanergy Maritime Holdings Corp.Seanergy Maritime Holdings Corp. is the only pure-play Capesize ship-owner publicly listed in the US. Seanergy provides marine dry bulk transportation services through a modern fleet of Capesize vessels. Upon delivery of the latest acquisition of the Company, which is scheduled for the first week of August 2020, Seanergy’s operating fleet will consist of 11 Capesize vessels with an average age of 11.5 years and aggregate cargo carrying capacity...

Continue reading

Logansport Financial Corp. Reports Net Earnings for the Quarter Ended June 30, 2020

LOGANSPORT, Ind., July 15, 2020 (GLOBE NEWSWIRE) — Logansport Financial Corp., (OTCBB,  LOGN), parent company of Logansport Savings Bank, reported net earnings for the quarter ended June 30, 2020 of $879,000 or $1.44 per diluted share, compared to earnings in 2019 of $561,000 or $.91 per diluted share. Year to date the company reported net earnings of $1,492,000 for 2020 compared to $1,061,000 for 2019. Diluted earnings per share for the six months ended June 30, 2020 were $2.44 compared to $1.72 for the six months ended June 30, 2019. Total assets at June 30, 2020 were $221.6 million compared to total assets at June 30, 2019 of $183.4 million. Total Deposits at June 30, 2020 were $193.3 million compared to total deposits of $158.3 million at June 30, 2019.The statements contained in this press release contain forward-looking statements...

Continue reading

Planet Media SA : SILVERTECH : PLANET MEDIA BOUSCULE LE SECTEUR AVEC LE LANCEMENT DE SA PLATEFORME DE SERVICE DIGITAL RETRAITE, ZEST

SILVERTECH : PLANET MEDIA BOUSCULE LE SECTEUR AVEC LE LANCEMENT DE SA PLATEFORME DE SERVICE DIGITAL RETRAITE, ZESTParis, le 15 juillet 2020 –En 2030, la France comptera 20 millions de retraités, soit un tiers de la population française. Fort de ce constat et de 20 ans d’expérience dans le domaine et à la demande de ses abonnés, Planet Media – leader en France des contenus et services pour les seniors connectés et éditeur des sites Planet.fr et Medisite fr – lance Zest, une plateforme digitale 100% gratuite, pour aider les pré-retraités, les aidants et les retraités actifs à aborder sereinement cette étape de la vie. Zest les informe et les conseille mais surtout, face à la complexité et la multitude des offres existantes, les met en relation avec les bons partenaires. Trois rubriques sont d’ores et déjà disponibles : Mutuelle,...

Continue reading

KRONOS ADVANCED TECHNOLOGIES PLANS SHAREHOLDER MEETING AND TO BECOME AMERICA’S FIRST OTC PUBLIC BENEFIT CORPORATION, CITING PURPOSE, ACCOUNTABILITY AND TRANSPARENCY

Los Angeles, CA, July 15, 2020 (GLOBE NEWSWIRE) — Los Angeles, CA, July 15th, 2020 (GLOBE NEWSWIRE) – KRONOS ADVANCED TECHNOLOGIES, INC. (OTC MARKETS: KNOS) (“KNOS” or the “Company”), a product development and production company that has significantly changed the way air is moved, filtered, and sterilized, today announced that it has decided to transition into a Public Benefit Corporation, becoming one of very few publicly traded companies that have modified their obligations to public shareholders, committing to higher standards of purpose in their business practices. To put it simply, KNOS has committed to ensuring that the interest of consumers’ wellbeing is at the core of its corporate operating principles — as opposed to holding profits as its one and only end goal.“Purpose, accountability,...

Continue reading

DNV3837 antibiotic candidate: the Phase II trial continues in the US

DNV3837 antibiotic candidate: the Phase II trial continues in the United States, despite a disrupted context due to the COVID-19 outbreak DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that uses its lead generation platform to develop innovative anti-infective drugs, is pursuing the Phase II clinical trial of its antibiotic candidate DNV3837, in a context where U.S. hospitals are still fighting the COVID-19 pandemic. The Company thanks the clinicians for their commitment to this trial, as they face an unprecedented health crisis.DNV3837 targets the treatment of Clostridioides difficile gastrointestinal infections (CDI), a pathogen classified as urgent threat by the U.S. Centers for Disease Control and Prevention (CDC). A Phase II clinical trial, launched in early 2020 in the United States, is evaluating the efficacy of...

Continue reading

Guerbet Optimizes its Industrial Network / Sale of the Montreal pharmaceutical site

Guerbet Optimizes its Industrial NetworkSale of the Montreal pharmaceutical siteVillepinte (France), July 15, 2020 – 18:00 CET – Guerbet (GBT) today announced the sale of its pharmaceutical site in Montreal (Canada) to MedXL, a specialist in medical devices and sterile pre-filled syringes.The Montreal industrial facility specializes on the one hand in filling and finishing of contrast media and on the other in the large-series manufacture of syringes pre-filled with sterile solutions for third parties, which is not a core business for Guerbet. Guerbet will gradually transfer its contrast agent production, carried out previously in Montreal, to its pharmaceutical sites in France and the USA.Guerbet sells this site as part of its plans to optimize its industrial network. The operation will make Guerbet more competitive by improving...

Continue reading

Optimisation du schéma industriel du Groupe / Vente du site pharmaceutique de Montréal

Optimisation du schéma industriel du GroupeVente du site pharmaceutique de MontréalVillepinte (France), le 15 juillet 2020 – 18h00 CET – Guerbet (GBT) annonce aujourd’hui la vente à MedXL, spécialiste des dispositifs médicaux et seringues pré-remplies stériles, de son site pharmaceutique de Montréal (Canada).Le site industriel de Montréal est spécialisé d’une part dans la mise en solution et le remplissage de produits de contraste et d’autre part dans la fabrication en très grandes séries de seringues pré remplies de solutions stérilisées pour compte de tiers, activité non stratégique pour Guerbet. La fabrication des produits de contraste jusqu’ici réalisée à Montréal sera progressivement transférée dans les sites pharmaceutiques de Guerbet en France et aux USA.La cession de ce site fait partie de l’optimisation du réseau industriel...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.